A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)

Excluded: MSH2 MSI-H

Have confirmed MSI-H CRC (gene test)

Cannot have received: systemic anti-tumor drug treatment

Exception: neoadjuvant/adjuvant therapy completed >12 months before recurrence/progression

Have not received any previous systemic anti-tumor drug treatment for metastatic colorectal adenocarcinoma; For participants who have previously received neoadjuvant/adjuvant therapy, the time from the last treatment to recurrence or progression must exceed 12 months.

Cannot have received: radiotherapy

Exception: palliative radiotherapy for bone disorders at least 14 days prior to initiation of study treatment

Have received radiotherapy within 6 months prior to the initiation of study treatment, except for palliative radiotherapy for bone disorders at least 14 days prior to initiation of study treatment; radiotherapy covering more than 30% of the bone marrow area within 28 days prior to randomization is not allowed.

Cannot have received: major surgery

Have received major surgery within 28 days prior to randomization. A major surgery in this study is defined as a surgery requiring at least 3 weeks of recovery to be able to receive the treatment in this study